Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H25FO5S |
| Molecular Weight | 443.518 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1CC2=CC=C(S2)C3=CC=C([18F])C=C3)[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O
InChI
InChIKey=XTNGUQKDFGDXSJ-ILGLIWPDSA-N
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1/i25-1
| Molecular Formula | C24H25FO5S |
| Molecular Weight | 443.518 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 12:05:05 GMT 2025
by
admin
on
Wed Apr 02 12:05:05 GMT 2025
|
| Record UNII |
XAR27Q37KR
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
XAR27Q37KR
Created by
admin on Wed Apr 02 12:05:05 GMT 2025 , Edited by admin on Wed Apr 02 12:05:05 GMT 2025
|
PRIMARY | |||
|
90440019
Created by
admin on Wed Apr 02 12:05:05 GMT 2025 , Edited by admin on Wed Apr 02 12:05:05 GMT 2025
|
PRIMARY | |||
|
1415906-04-5
Created by
admin on Wed Apr 02 12:05:05 GMT 2025 , Edited by admin on Wed Apr 02 12:05:05 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
NON-LABELED -> LABELED |
|
||
|
|
TARGET->RADIOLIGAND |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
||||
| Volume of Distribution | PHARMACOKINETIC |
|
AT STEADY-STATE |
|||
| Biological Half-life | PHARMACOKINETIC |
|
SINGLE DOSE |
|||
| Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|||
| Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |